Laura J. Zitella

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Laura J. Zitella

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Nurse Practitioner, Associate Clinical Professor, University of California San Francisco

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Nurse Practitioner, Associate Clinical Professor, University of California San Francisco

Laura J. Zitella is a nurse practitioner in the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program and Associate Clinical Professor in the Department of Physiological Nursing at the University of California San Francisco. She earned her Master of Science from the University of Illinois in Chicago and holds certifications as an acute care nurse practitioner and an advanced oncology certified nurse.

Her clinical expertise includes patients with hematologic malignancies receiving chemotherapy, immunotherapy, targeted therapy, investigational agents, hematopoietic cell transplantation, and supportive care. She is a prominent educator who has delivered hundreds of educational presentations to national and international audiences and authored numerous peer-reviewed publications, web courses, videos, and book chapters. Laura co-edited the Hematologic Malignancies in Adults textbook, which was awarded an American Medical Writers Association Medical Book Award Honorable Mention.

Laura is actively involved with the Advance Practice Provider Oncology Summit, Advanced Practitioner Society for Hematology and Oncology, the Oncology Nursing Society, and the CLL Society. She serves on medical advisory board of the CLL Society, the Journal of Advanced Practitioner in Oncology editorial board, and several oncology conference planning committees. She is the proud recipient of the ONS Excellence in Medical Oncology award, the DAISY award, and the inaugural Stanford Health Care Advanced Practice Provider of the Year award.

Laura's Shared Resources

High-Risk Multiple Myeloma: New Definitions, Diagnostics, and Promising Therapies

Despite significant advancements in multiple myeloma (MM) treatment, a quarter of newly diagnosed patients survive less than three years, particularly those with high-risk MM. This aggressive subset, representing about 20%...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Study Reveals Need for Better Therapies in Triple-Class Exposed Multiple Myeloma

The LocoMMotion study, a multinational prospective observational trial, examined the effectiveness and safety of real-world clinical practice treatments in triple-class exposed patients with multiple myeloma who had received proteasome inhibitors,...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Supportive Care Key to Managing Side Effects in Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy in the United States. Advances in treatments such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and stem cell transplants have...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Provided by an unrestricted grant from

Provided by an unrestricted grant from

Share